These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 30524732)

  • 1. Patent challenges in the procurement and supply of generic new essential medicines and lessons from HIV in the southern African development community (SADC) region.
    't Hoen EFM; Kujinga T; Boulet P
    J Pharm Policy Pract; 2018; 11():31. PubMed ID: 30524732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medicine procurement and the use of flexibilities in the Agreement on Trade-Related Aspects of Intellectual Property Rights, 2001-2016.
    't Hoen EF; Veraldi J; Toebes B; Hogerzeil HV
    Bull World Health Organ; 2018 Mar; 96(3):185-193. PubMed ID: 29531417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of intellectual property rights on access to medicines in the WHO African region: 25 years after the TRIPS agreement.
    Motari M; Nikiema JB; Kasilo OMJ; Kniazkov S; Loua A; Sougou A; Tumusiime P
    BMC Public Health; 2021 Mar; 21(1):490. PubMed ID: 33706726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A method for understanding generic procurement of HIV medicines by developing countries with patent protection.
    Beall RF; Attaran A
    Soc Sci Med; 2017 Jul; 185():118-126. PubMed ID: 28578209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What is the impact of intellectual property rules on access to medicines? A systematic review.
    Tenni B; Moir HVJ; Townsend B; Kilic B; Farrell AM; Keegel T; Gleeson D
    Global Health; 2022 Apr; 18(1):40. PubMed ID: 35428250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trade-Related Aspects of Intellectual Property Rights Flexibilities and Public Health: Implementation of Compulsory Licensing Provisions into National Patent Legislation.
    McGIVERN L
    Milbank Q; 2023 Dec; 101(4):1280-1303. PubMed ID: 37646392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Driving a decade of change: HIV/AIDS, patents and access to medicines for all.
    Hoen E'; Berger J; Calmy A; Moon S
    J Int AIDS Soc; 2011 Mar; 14():15. PubMed ID: 21439089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does the political will exist to bring quality-assured and affordable drugs to low- and middle-income countries?
    Beck EJ; Mandalia S; DongmoNguimfack B; Pinheiro E; 't Hoen E; Boulet P; Stover J; Gupta A; Juneja S; Habiyambere V; Ghys P; Nunez C
    Glob Health Action; 2019; 12(1):1586317. PubMed ID: 30983547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TRIPS to Where? A Narrative Review of the Empirical Literature on Intellectual Property Licensing Models to Promote Global Diffusion of Essential Medicines.
    Mermelstein S; Stevens H
    Pharmaceutics; 2021 Dec; 14(1):. PubMed ID: 35056944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A lifeline to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countries.
    Waning B; Diedrichsen E; Moon S
    J Int AIDS Soc; 2010 Sep; 13():35. PubMed ID: 20840741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soaring antiretroviral prices, TRIPS and TRIPS flexibilities: a burning issue for antiretroviral treatment scale-up in developing countries.
    Orsi F; d'almeida C
    Curr Opin HIV AIDS; 2010 May; 5(3):237-41. PubMed ID: 20539080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?
    Oliveira MA; Bermudez JA; Chaves GC; Velásquez G
    Bull World Health Organ; 2004 Nov; 82(11):815-21. PubMed ID: 15640916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Access to hepatitis C virus treatment: Lessons from implementation of strategies for increasing access to antiretroviral treatment.
    Assefa Y; Hill PS; Williams OD
    Int J Infect Dis; 2018 May; 70():65-68. PubMed ID: 29550446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Product patents and access to innovative medicines.
    Dai R; Watal J
    Soc Sci Med; 2021 Dec; 291():114479. PubMed ID: 34700119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evolution of the international intellectual property rights system: patent protection for the pharmaceutical industry and access to medicines].
    Chaves GC; Oliveira MA; Hasenclever L; de Melo LM
    Cad Saude Publica; 2007 Feb; 23(2):257-67. PubMed ID: 17221075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes to intellectual property policy in South Africa: putting a stop to evergreening?
    Hill JE
    Expert Opin Ther Pat; 2014 Aug; 24(8):839-43. PubMed ID: 24965317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Public health-oriented intellectual property and trade policies in Africa and the regional mechanism under Trade-Related Aspects of Intellectual Property Rights amendment.
    Adekola TA
    Public Health; 2019 Aug; 173():1-4. PubMed ID: 31203136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promotion of access to essential medicines for non-communicable diseases: practical implications of the UN political declaration.
    Hogerzeil HV; Liberman J; Wirtz VJ; Kishore SP; Selvaraj S; Kiddell-Monroe R; Mwangi-Powell FN; von Schoen-Angerer T;
    Lancet; 2013 Feb; 381(9867):680-9. PubMed ID: 23410612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The make or buy debate: considering the limitations of domestic production in Tanzania.
    Wilson KR; Kohler JC; Ovtcharenko N
    Global Health; 2012 Jun; 8():20. PubMed ID: 22747578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Data exclusivity exceptions and compulsory licensing to promote generic medicines in the European Union:
    't Hoen EFM; Boulet P; Baker BK
    J Pharm Policy Pract; 2017; 10():19. PubMed ID: 28670455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.